BMRN - バイオマリン・ファ―マシュ―ティカルズ (BioMarin Pharmaceutical Inc.) バイオマリン・ファ―マシュ―ティカルズ

 BMRNのチャート


 BMRNの企業情報

symbol BMRN
会社名 BioMarin Pharmaceutical Inc. (バイオマリン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 バイオマリン・ファーマスーティカル(BioMarin Pharmaceutical Inc.)はバイオテクノロジ企業である。同社はさまざまな病気や病状に対して医薬品の開発と商業化を行う。2016年12月31日現在、同社の治療ポートフォリオは五つの承認医薬品、複数の臨床および前臨床製品候補から構成される。同社の承認医薬品はムコ多糖症I(MPS I)向けのアルデュラザイム(ラロニダーゼ)、ランバートイートン重症筋症(LEMS)向けのファーデサル(リン酸アミンピリジン)、フェニルケトン尿症(PKU)向けのクワン(サプロプテリン二塩酸塩)、ムコ多糖症VI(MPS VI)向けのナガラザイム(ガルスルファイゼ)、ムコ多糖症IV型A(MPS IV A)向けのVimizim (elosulfase alpha)などを含む。同社の臨床候補薬はBrineura、pegvaliase、vosoritide、BMN 270とBMN 250を含む。   バイオマリン・ファ―マシュ―ティカルズは、米国の医薬品メ―カ―。主製品は承認薬5品:ムコ多糖症I治療薬Aldurazyme、ムコ多糖症VI治療薬Naglazyme、フェニルケトン尿症治療薬Kuvan、ランバ―トイ―トン筋無力症候群治療薬Firdapse、ムコ多糖症IV・モルキオ症候群タイプA・リソソ―ム蓄積障害治療薬VIMIZIM。   
本社所在地 770 Lindaro Street San Rafael CA 94901 USA
代表者氏名 Jean-Jacques Bienaime ジャン=ジャックビエナイム
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 415-506-6700
設立年月日 35339
市場名 NASDAQ National Market System
ipoyear 1999年
従業員数 2581人
url www.biomarin.com
nasdaq_url https://www.nasdaq.com/symbol/bmrn
adr_tso
EBITDA EBITDA(百万ドル) -87.42600
終値(lastsale) 101.39
時価総額(marketcap) 18005888222.64
時価総額 時価総額(百万ドル) 18517.35
売上高 売上高(百万ドル) 1438.745
企業価値(EV) 企業価値(EV)(百万ドル) 18345.9
当期純利益 当期純利益(百万ドル) -87.16000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioMarin Pharmaceutical Inc. revenues increased 20% to $746.3M. Net loss before extraordinary items increased 23% to $65.5M. Revenues reflect United States segment increase of 29% to $353.4M Europe segment increase of 36% to $178.6M. Higher net loss reflects Research and development - Balancing val increase of 26% to $330.7M (expense) Selling General and Admin - Bal Val increase of 13% to $259.4M (expense).

 BMRNのテクニカル分析


 BMRNのニュース

   BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A  2021/03/08 13:31:00 PR Newswire
SAN RAFAEL, Calif., March 8, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene roxaparvovec, an investigational gene therapy…
   Sebastiani Vineyards names new winemaker  2021/03/05 02:06:00 North Bay Business
Mark Beaman has worked for Sonoma, Mendocino and Washington state vintners. Other news from Fetzer, Visit Napa Valley, BioMarin, To Celebrate Life, West Marin Fund and Vivalon.
   Anthem, BioMarin, CRISPR, GE and More Thursday Afternoon Analyst Calls  2021/03/04 17:25:33 24/7 Wall street
   BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia  2021/03/03 13:31:00 PR Newswire
SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type…
   Cork pharma firm BioMarin is focused on cures for rare diseases  2021/03/02 12:10:09 The Cork
2 March 2021 By Tom Collins tom@TheCork.ie Global biopharmaceutical company BioMarin lights up for Rare Disease Day BioMarin Pharmaceutical Inc. last week illuminated its sites in Shanbally, Cork and Earlsfort Terrace, Dublin to signify the Company’s commitment to supporting rare disease patients. Across the globe, buildings were lit up in support of Rare Disease Day…
   BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia  2021/03/03 13:31:00 PR Newswire
SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type…
   Cork pharma firm BioMarin is focused on cures for rare diseases  2021/03/02 12:10:09 The Cork
2 March 2021 By Tom Collins tom@TheCork.ie Global biopharmaceutical company BioMarin lights up for Rare Disease Day BioMarin Pharmaceutical Inc. last week illuminated its sites in Shanbally, Cork and Earlsfort Terrace, Dublin to signify the Company’s commitment to supporting rare disease patients. Across the globe, buildings were lit up in support of Rare Disease Day…
   Mucopolysaccharidosis (MPS) Treatment Market Coronavirus (COVID-19) Impact Analysis with Size, Share, Prospects, Crucial Players, Competitive Breakdown and Regional Forecast by 2029 with Sanofi S.A., Shire, BioMarin Pharmaceutical Inc., Ultragenyx Pharmac  2021/03/02 07:35:07 OpenPR
Competition Landscape In this chapter, readers can find a comprehensive list of all the leading manufacturers in the mucopolysaccharidosis treatment market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments.
   Cell and Gene Therapy Market – Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals  2021/03/02 07:30:17 OpenPR
Cell and Gene Therapy Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Canaccord Genuity Stick to Their Buy Rating for BioMarin Pharmaceutical By Investing.com  2021/03/01 20:25:01 Investing.com
Canaccord Genuity Stick to Their Buy Rating for BioMarin Pharmaceutical
   Intel, BioMarin, Avid Technology Stocks Chosen by Wall Street Analysts as Earnings Season Is Here  2021/01/18 13:10:24 Coinspeaker
Analysts have picked up the stocks with three companies with renewed price targets, this list includes Intel, BioMarin, Avid Technology.
   Why top market analysts back stocks like Intel, BioMarin - News For Forex  2021/01/17 14:16:00 News For Forex
Intel logo exhibited during the Mobile World Congress, on February 28, 2019 in Barcelona, Spain. Joan Cros | NurPhoto | Getty Images Earnings season is here, and Wall Street analysts are calling for another decline amid the pandemic. However, some pros are more optimistic about the fourth quarter earnings season, with Ignacio Cantos, investment director […]
   FXNEWS24 |Why top market analysts back stocks like Intel, BioMarin | UK Forex Reviews  2021/01/17 13:40:09 FXNews24
Why top market analysts back stocks like Intel, BioMarin | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Why high market analysts again shares like Intel, BioMarin - EAST AUTO NEWS - EAST AUTO NEWS & TRENDS  2021/01/17 13:23:58 EASTAUTO News
East Auto News the news magazine for cars, industry, politics, markets and economy, motorsports and much more
   BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN  2021/01/16 03:50:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). On August 19, 2020, the Company disclosed that it received a Complete Response Letter (“CRL”) from the FDA rejecting its Biologics License Application (“BLA”) for its product, valoctocogene roxaparvovec, and recommending two years of da

 関連キーワード  (医薬品 米国株 バイオマリン・ファ―マシュ―ティカルズ BMRN BioMarin Pharmaceutical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)